The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Carboplatin hypersensitivity reactions (HSR) in carboplatin retreatment for recurrent ovarian cancer.
 
Roisin Eilish O'Cearbhaill
Research Funding - Janssen Research & Development (Inst); Juno Therapeutics (Inst); OncoMed (Inst)
 
David Michael Hyman
Consulting or Advisory Role - Chugai Pharma; Santa Maria Biotherapeutics
Patents, Royalties, Other Intellectual Property - Trovagene (Inst)
Travel, Accommodations, Expenses - Puma Biotechnology
 
William P. Tew
No Relationships to Disclose
 
Alexia Iasonos
No Relationships to Disclose
 
Nicholas A Cangemi
No Relationships to Disclose
 
Carol Aghajanian
Consulting or Advisory Role - AstraZeneca
Travel, Accommodations, Expenses - Abbvie; AstraZeneca
 
Katherine M. Bell-McGuinn
Consulting or Advisory Role - Clovis Oncology
Travel, Accommodations, Expenses - Abbvie
 
Vicky Makker
Research Funding - Karyopharm Therapeutics (Inst)
 
Martee Leigh Hensley
Employment - Sanofi (I)
Consulting or Advisory Role - EMD Serono; Insys Therapeutics
Research Funding - Johnson & Johnson (Inst)
Patents, Royalties, Other Intellectual Property - author, Up to Date
 
Jason A. Konner
Research Funding - Aeterna Zentaris (Inst)
 
Rachel N. Grisham
Consulting or Advisory Role - Amgen
Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Medivation (Inst)
 
Katherine Diaz-Macinnis
No Relationships to Disclose
 
Paul Sabbatini
Research Funding - Janssen Oncology (Inst); OncoMed (Inst)
 
David R. Spriggs
Patents, Royalties, Other Intellectual Property - Through my laboratory, we haver discovered anti-MUC16 antibodies that MSKCC has filed patents about. These patents, if commercialized could ultimately result in royalties paid to me. (Inst)